Julian Andreev, Ph.D.
Affiliations: | New York University, New York, NY, United States |
Area:
tyrosine phosphorylationGoogle:
"Julian Andreev"Mean distance: 16.26 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Joseph Schlessinger | grad student | 2000 | NYU | |
| (Identification and characterization of targets and potential effectors of the non-receptor protein tyrosine kinase Pyk2.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bay AP, Faulkner D, Tiwari S, et al. (2020) Abstract 2898: A biparatopic HER2xHER2 antibody drug conjugate with potent anti-tumor activity Cancer Research. 80: 2898-2898 |
| DaSilva JO, Yang K, Perez Bay AE, et al. (2019) A biparatopic antibody that modulates MET trafficking exhibits enhanced efficacy compared to parental antibodies in MET-driven tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Bay AP, Kalsy A, Tiwari S, et al. (2019) Abstract 233: Bispecific HER2 ADC: Making more potent HER2 ADC by improving target internalization Cancer Research. 79: 233-233 |
| Kelly MP, Hickey C, Makonnen S, et al. (2017) Preclinical activity of the novel anti-Prolactin Receptor (PRLR) antibody drug-conjugate REGN2878-DM1 in PRLR positive breast cancers. Molecular Cancer Therapeutics |
| Andreev J, Thambi N, Perez Bay AE, et al. (2017) Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Molecular Cancer Therapeutics |
| Kuhnert F, Chen G, Coetzee S, et al. (2015) Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer. Cancer Research |
| Kelly MP, Coetzee S, Hickey C, et al. (2015) Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer Molecular Cancer Therapeutics. 14 |
| Andreev J, Thambi N, Delfino F, et al. (2015) Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC) Molecular Cancer Therapeutics. 14 |
| Andreev J, Galisteo ML, Kranenburg O, et al. (2001) Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. The Journal of Biological Chemistry. 276: 20130-5 |
| Mandiyan V, Andreev J, Schlessinger J, et al. (1999) Crystal structure of the ARF-GAP domain and ankyrin repeats of PYK2-associated protein beta. The Embo Journal. 18: 6890-8 |